Asklepios BioPharmaceutical, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Asklepios BioPharmaceutical, Inc.
A new gene therapy deal between Takeda and Belief signals multinationals are continuing to increase the pace of collaboration with Chinese partners as a source of innovation.
The German group has invested $250m into a facility at its campus in Berkeley, CA to produce cell therapies from its own portfolio and for other companies in the space who are looking to tackle the perennial issue of manufacturing.
Private Company Edition: ReCode’s series B venture capital round grew for a third time, now totaling $260m for precision genetic medicines. Also, DalCor closed an $80m series D, manufacturer Nephron amassed $350m, Hyku launched with a $56m seed financing and Magnet emerged with $50m.
Bayer pharma research head Christian Rommel has told Scrip he was excited about the Phase I data on Parkinson's disease prospect bemdaneprocel, which is comprised of dopamine-producing neurons derived from pluripotent stem cells, but also advocated caution at this early stage.
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Other Names / Subsidiaries
- Actus Therapeutics, Inc.
- Synpromics, Ltd.
- RoverMed BioSciences
- NanoCor Therapeutics
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.